Abstract
Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be enabled by improved preclinical approaches that more effectively inform and ensure safe selection of clinical candidates and drug combination/regimens. An evidence-based approach for the assessment of nonclinical models supporting TB drug development has been proposed by a joint partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the Critical Path to TB Drug Regimens (CPTR) Consortium.
Original language | English (US) |
---|---|
Pages (from-to) | 1177-1182 |
Number of pages | 6 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 60 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2016 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases